Clinical Trial Update: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates the efficacy/safety of encorafenib, binimetinib, and cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• Cetuximab (cetuximab)
• Encorafenib (encorafenib)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-08-30